Tom 14, Nr 4 (2023)
Inne materiały uzgodnione z Redakcją
Opublikowany online: 2024-01-04
Wyświetlenia strony
96
Wyświetlenia/pobrania artykułu
5
Wady i zalety stosowania intermittent fasting u chorych otyłych i osób zdrowych
Forum Zaburzeń Metabolicznych 2023;14(4):153-159.
Streszczenie
W dobie pandemii otyłości coraz więcej uwagi zwraca się na niefarmakologiczne metody leczenia otyłości. Otyłość wiąże się z licznymi konsekwencjami zdrowotnymi i stanowi istotne wyzwanie i obciążenie ekonomiczne dla krajów i ochrony zdrowia na świecie. W tym kontekście obiecujące wydaje się wdrażanie personalizowanych schematów żywieniowych dostosowanych do możliwości chorego otyłego. Modnym i szeroko stosowanym jest wariantem jest intermittent fasing (IF), którego różne odmiany są obecnie przedmiotem badań oraz wielu dyskusji. Najważniejsze z nich to: alternate-day fasting (ADF), dieta 5:2 oraz dieta time-restricted feeding (TRF) z modyfikacjami. Stosowanie IF wpływa na metabolizm i prowadzi do licznych zmian: m.in. redukcji masy ciała, składu ciała, wskaźników ryzyka sercowo-naczyniowego, przemian węglowodanów i tłuszczów. Wydaje się, że w określonych przypadkach chorych otyłych może stanowić element terapeutyczny istotny w prewencji rozwoju chorób dietozależnych.
Słowa kluczowe: post przerywanyotyłośćnadwagadieta
Referencje
- World Obesity Atlas 2022. World Obesity Federation. London: 2022. https://s3-eu-west-1.amazonaws.com/wof-files/World_Obesity_Atlas_2022.pdf (25 November 2023).
- Anekwe CV, Jarrell AR, Townsend MJ, et al. Socioeconomics of Obesity. Curr Obes Rep. 2020; 9(3): 272–279.
- Gadde KM, Martin CK, Berthoud HR, et al. Obesity: Pathophysiology and Management. J Am Coll Cardiol. 2018; 71(1): 69–84.
- Cornier MA. A review of current guidelines for the treatment of obesity. Am J Manag Care. 2022; 28(15 Suppl): S288–S296.
- Garvey WT, Mechanick JI, Brett EM, et al. Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. Endocr Pract. 2016; 22 Suppl 3: 1–203.
- U.S. Department of Agriculture. U.S. Department of Health and Human Services. Dietary Guidelines for Americans, 2020–2025. 9th ed. U.S. Department of Health and Human Services; Washington, DC, USA: 2020. https://www.dietaryguidelines.gov/resources/2020-2025-dietary-guidelines-online-materials (25 November 2023).
- Hofer SJ, Carmona-Gutierrez D, Mueller MI, et al. The ups and downs of caloric restriction and fasting: from molecular effects to clinical application. EMBO Mol Med. 2022; 14(1): e14418.
- Patikorn C, Roubal K, Veettil SK, et al. Intermittent Fasting and Obesity-Related Health Outcomes: An Umbrella Review of Meta-analyses of Randomized Clinical Trials. JAMA Netw Open. 2021; 4(12): e2139558.
- Jamshed H, Beyl RA, Della Manna DL, et al. Early Time-Restricted Feeding Improves 24-Hour Glucose Levels and Affects Markers of the Circadian Clock, Aging, and Autophagy in Humans. Nutrients. 2019; 11(6).
- Moon S, Kang J, Kim SH, et al. Beneficial Effects of Time-Restricted Eating on Metabolic Diseases: A Systemic Review and Meta-Analysis. Nutrients. 2020; 12(5).
- Meng H, Zhu L, Kord-Varkaneh H, et al. Effects of intermittent fasting and energy-restricted diets on lipid profile: A systematic review and meta-analysis. Nutrition. 2020; 77: 110801.
- Anton SD, Moehl K, Donahoo WT, et al. Flipping the Metabolic Switch: Understanding and Applying the Health Benefits of Fasting. Obesity (Silver Spring). 2018; 26(2): 254–268.
- Puchalska P, Crawford PA. Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics. Cell Metab. 2017; 25(2): 262–284.
- Stekovic S, Hofer SJ, Tripolt N, et al. Alternate Day Fasting Improves Physiological and Molecular Markers of Aging in Healthy, Non-obese Humans. Cell Metab. 2019; 30(3): 462–476.e6.
- Harvie MN, Pegington M, Mattson MP, et al. The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes (Lond). 2011; 35(5): 714–727.
- Stubbs B, Cox P, Evans R, et al. A Ketone Ester Drink Lowers Human Ghrelin and Appetite. Obesity. 2017; 26(2): 269–273.
- Kim S, Park DH, Lee SH, et al. Contribution of High-Intensity Interval Exercise in the Fasted State to Fat Browning: Potential Roles of Lactate and β-Hydroxybutyrate. Med Sci Sports Exerc. 2023; 55(7): 1160–1171.
- Allard JS, Heilbronn LK, Smith C, et al. Pennington CALERIE Team. In vitro cellular adaptations of indicators of longevity in response to treatment with serum collected from humans on calorie restricted diets. PLoS One. 2008; 3(9): e3211.
- Brocchi A, Rebelos E, Dardano A, et al. Effects of Intermittent Fasting on Brain Metabolism. Nutrients. 2022; 14(6).
- Ylli D, Sidhu S, Parikh T, et al. Endocrine Changes in Obesity. Endotext [Internet]. South Dartmouth (MA): MDText. 2022.
- Moro T, Tinsley G, Pacelli FQ, et al. Twelve Months of Time-restricted Eating and Resistance Training Improves Inflammatory Markers and Cardiometabolic Risk Factors. Med Sci Sports Exerc. 2021; 53(12): 2577–2585.
- Martens CR, Rossman MJ, Mazzo MR, et al. Short-term time-restricted feeding is safe and feasible in non-obese healthy midlife and older adults. Geroscience. 2020; 42(2): 667–686.
- Domaszewski P, Konieczny M, Dybek T, et al. Comparison of the effects of six-week time-restricted eating on weight loss, body composition, and visceral fat in overweight older men and women. Exp Gerontol. 2023; 174: 112116.
- He M, Wang J, Liang Q, et al. Time-restricted eating with or without low-carbohydrate diet reduces visceral fat and improves metabolic syndrome: A randomized trial. Cell Rep Med. 2022; 3(10): 100777.
- Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013; 93(1): 359–404.
- Villareal DT, Fontana L, Das SK, et al. CALERIE Study Group. Effect of Two-Year Caloric Restriction on Bone Metabolism and Bone Mineral Density in Non-Obese Younger Adults: A Randomized Clinical Trial. J Bone Miner Res. 2016; 31(1): 40–51.
